Ista Pharmaceuticals Inc.
- Share via
The Irvine developer of products to treat eye disease reported a third-quarter net loss of $5.5 million, or 70 cents a share, compared with a net loss of $2.8 million, or $1.84 a share, for the same period last year. No revenue was reported.
